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VogteKoyanagieHarada (VKH) disease is a bilateral,
chronic granulomatous panuveitis associated with central
nervous system, auditory, and integumentary manifestations.
Classically, the disease begins with a prodromal phase of
neuroauditory symptoms, followed by an acute uveitis phase,
and finally, the chronic stage manifestations. However, it is
not uncommon for patients with initial-onset VKH disease to
present with the isolated ocular disease, without associated
neuroauditory symptoms.1 Any delay in establishing the
correct diagnosis of initial-onset VKH disease and in ini-
tiating adequate treatment may result in higher risks of
chronicity, complications, and visual impairment.2,3 There-
fore, accurate recognition of the distinctive ocular features
associated with the initial-onset VKH will help to establish
an early definitive diagnosis, with prompt initiation of
appropriate treatment.
Several criteria have been proposed to clarify the diagnostic
approach for VKH disease. In 1978, Sugiura suggested a set of
criteria for the diagnosis of VKH disease. Bilateral ocular
inflammation, especially with posterior manifestations, along
with typical fluorescein angiography findings and pleocytosis
of the cerebrospinal fluid were required criteria for the diag-
nosis.4 Although this was an immense step in outlining the
features of VKH, his criteria were not sensitive enough to
diagnose patients after the acute presentation. Moreover, the
necessity of obtaining cerebrospinal fluid limited its applica-
tion in many countries. Two years later, the American Society
of Uveitis (AUS) redefined Sugiura’s criteria by detailing the
posterior uveitis manifestations and extending the items ofrs declare no conflict of interest.
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/creativecommons.org/licenses/by-nc-nd/4.0/).neuroauditory signs.5 The AUS criteria did not include pleo-
cytosis as a required criterion for diagnosis but considered it
part of the neuroauditory signs. Because sympathetic oph-
thalmia was not clinically distinguishable from VKH, “lack of
history of trauma or surgery” was set as a prerequisite for
diagnosis. However, the fluorescein angiography findings,
which were an important clue during the acute stage of dis-
ease, failed to be mentioned. Similar to Sugiura’s criteria, the
AUS criteria failed to differentiate between acute and chronic
stages of the disease.
In 1999, the first VKH International Workshop group pro-
posed the revised diagnostic criteria for VKH disease. It aimed
to overcome the shortcomings of previous criteria, in partic-
ular, boosting up the sensitivity and specificity.6 The ocular
manifestations were described in more detail and fluorescein
angiography, and ultrasonography findings were adopted as
useful ancillary tests for the diagnosis. Moreover, it catego-
rized the VKH patients into three groups: (1) complete, (2)
incomplete, and (3) probable based on the presence of ocular
and extraocular manifestations.
Our purpose here is to explain, based on recent data, why
the revised diagnostic criteria for VKH disease failed to
improve management and should be reconsidered from the
perspective of reaching a rapid diagnosis of initial-onset dis-
ease. Limitations of the revised criteria currently include: (1)
not clearly differentiating initial-onset disease from chronic
disease, which has a crucial impact on management; (2)
division into three groups, which have very little clinical
relevance; and (3) not considering highly sensitive inves-
tigations such as indocyanine green angiography (ICGA),
spectral domain optical coherence tomography (SD-OCT),
and high-penetration imaging techniques of OCT [enhanced
depth imaging optical coherence tomography (EDI-OCT) and
swept source OCT].sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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segregated properlyThere is a growing body of evidence that underlines the
importance of segregating the different evolutional stages of
disease into initial-onset and chronic stages with varying
intrinsic behaviors, courses, and prognoses. Identifying initial-
onset ocular disease with or without associated neuroauditory
signs is crucial, as it is a potentially curable condition when
treated aggressively with dual steroidal and non-steroidal
immunosuppressive therapy.7e9 If the patient is treated prop-
erly at the early stage of disease onset, he or she may never
reach the chronic stages, and chronic ocular and integu-
mentary signs may never occur.2,3 On the other hand, the
chronic disease that is associated with chronic ocular signs and
integumentary manifestations results from late or insufficient
treatment of initial-onset disease. Acute signs are no longer
present at this stage. The disease will also have a different
clinical course in the chronic stages where it is more vulner-
able to recurrences and more resistant to treatment.10e12
Although the revised criteria partially addressed the acute
and chronic manifestations, the importance of such a dis-
tinction was not put forward, and they did not discriminate
between the different natural behaviors and clinical courses
and, hence, did not contribute fundamentally to a better
appraisal of VKH disease.
Mixing up the different evolutional stages of the disease
also affects the result of studies on VKH. Remarkable dis-
similarities exist in reports on VKH patients with regard to
complications, visual outcomes, and proportions of disease
subcategories.13e16 Although these dissimilarities could be the
result of diverse ethnical characteristics or different ther-
apeutic approaches, it is also probable that they arise from
inaccurate recognition and allocation of patients to initial-
onset and chronic stages. These two conditions should not
be included in the same study and should be the object of
segregated studies.
Very recently, a new study on diagnostic criteria for VKH
was published by a Chinese group that segregated initial-onset
versus chronic disease in a very detailed fashion correspond-
ing to what occurs in real clinical situations.17 This article
contributed to make it clear in the mind of the clinician that
early-onset and late diseases have to be differentiated and are
quasi-different diseases as far as behavior and management are
concerned.Categorization of VKH patients as “complete,
incomplete, and probable” has limited clinical,
therapeutic, and prognostic implicationsThe usefulness of dividing the VKH patients into the three
groups has been challenged in previous studies. In the Sin-
gaporean population, Chee et al. did not find any association
between the clinical course and the final disease category of
VKH patients.18 In another retrospective study on 67 VKH
patients in Brazil, no association was found between the dis-
ease severity parameters (relapses, the presence of ocularcomplications, and the use of immunosuppressive therapy) and
disease categories, and hence, the authors doubted the clinical
and prognostic implications of such categorization.19
Early diagnosis and aggressive treatment have a significant
impact on the course of VKH disease. A patient with the initial-
onset disease will probably never reach the chronic phase if
treatment is started properly, and the patient may never show
the integumentary signs fulfilling the “complete” criteria.3
Therefore, having a specific type of VKH (complete, incom-
plete, or probable) is more influenced by treatment strategy and
timing, rather than the real nature of disease per se.
The signs and symptoms of VKH evolve over time. Patients
in the early phase of VKH disease rarely present with the
complete form because it includes both acute and chronic
signs, which obviously do not occur concomitantly. Rao and
associates applied the diagnostic criteria to 116 well-
documented patients with VKH.20 Although all the patients
fulfilled the criteria, none of the 22 patients in the early phase
group (symptoms lasting <4 weeks) was classified as complete
VKH. In another retrospective study on a Japanese population
of 41 VKH patients with the acute presentation, none of the
patients would be classified as having “complete” VKH, had
the revised diagnostic criteria been applied at two weeks after
disease onset.21
On the other hand, only a minor fraction of patients seen
after initial-onset disease could be categorized as “complete”.
In Rao’s study, only 22% of 88 patients in the late phase
fulfilled the criteria to be classified as “complete”.20 In another
study in Iran, in spite of rather a long follow-up time (median
28 months, range 6e228 months), only 4.5% of VKH patients
were classified as having the “complete” type of the disease.22
Similar observations were reported in other studies from
around the world when trying to classify VKH according to
the revised criteria.16,22e24 The reasons for the low proportion
of the “complete” VKH type are:
(1) As discussed earlier, prompt diagnosis and proper treat-
ment at disease onset may prevent the patient from passing
into chronic stages, and the patient may never manifest
integumentary signs to fulfill the “complete” criteria.
(2) Establishing the “complete” type mandates to obtain in
past disease history that there is evidence of acute pre-
sentation, which is not always feasible especially in those
patients who were first seen in chronic stages and were
initially treated by other primary care physicians during
the acute presentation. In a Japanese study, the revised
VKH criteria could not be applied in 5 out of 169 patients,
who had previously been diagnosed with VKH disease
(based on Sugiura’s criteria) and had an obvious sunset
glow fundus, as they were unable to obtain enough evi-
dence that could be used to document early
manifestations.24
After publication of the revised criteria, dozens of studies
were devoted to subdividing VKH series into the three cate-
gories, a theoretical exercise to no avail that did not contribute
to a better appraisal and management of the disease.
3Editorial / Journal of Current Ophthalmology 31 (2019) 1e7Failure to refer to and include imaging techniques that
precisely characterize stromal choroiditisImaging modalities, such as ICGA and to a lesser extent
EDI-OCT, give precise and very sensitive information on
choroiditis.25 Although ICGA was already well characterized
in VKH and routinely used in many countries at the time the
revised diagnostic criteria were generated, it was not inclu-
ded in the revised criteria.26 Several studies demonstrated
that ICGA findings are positive in close to 100% ofFig. 1. Case of initial-onset VogteKoyanagieHarada (VKH) disease at present
the onset of symptoms showing numerous hypofluorescent dark dots (HDDs) and
score ¼ 31)36 (1a). Many posterior pole HDDs and ICGA disc hyperfluorescence
hyperfluorescence (1c). Three weeks after combined systemic corticosteroid and c
decreased substantially (ICGA score ¼ 6) (1d). In the posterior pole, HDDs are ocases25,27 and hence, should be considered a disease-defining
criterion.
Due to less apparent choroidal signs during the very early
stage of choroiditis, the clinical diagnosis may be missed or
delayed when the revised diagnostic criteria are followed. The
inflammation in VKH starts from the choroidal stroma and
subsequently spreads towards the adjacent retina, optic nerve,
and vitreous body. In very early disease, the inflamed choroid
may not produce clinically detectable changes in the retina
(e.g., exudative retinal detachment) and remain occult.28 Usingation. Indocyanine green angiography (ICGA) performed about 10 days after
severe choroidal vasculitis (fuzzy unrecognizable choroidal vessels) (ICGA
indicating severe choroidal inflammation (1b). Fluorescein angiography disc
yclosporine therapy, choroidal vessels have a normal pattern, and HDDs have
nly faintly noted, and disc ICGA hyperfluorescence has disappeared (1e).
4 Editorial / Journal of Current Ophthalmology 31 (2019) 1e7ICGA and EDI-OCT, early choroidal involvement can be
detected, contributing to early diagnosis and treatment.29,30
In some patients, optic disc swelling is the initial ocular
presentation of VKH and serous retinal detachment is absent
or less remarkable.31 In a study by Okunuki, 14 out of 96
patients with acute VKH presented with optic disc swelling
while there was minimal or no serous retinal detachment.32
Interestingly, in six patients, there was no detectable serous
retinal detachment even on OCT, and only early manifes-
tations of choroiditis on ICGA enabled a diagnosis of VKH
disease. Kitumore acknowledged a similar limitation when
trying to diagnose VKH patients based on revised criteria.24
Furthermore, there are a few reports of VKH disease that
remained unilateral after a long follow-up. However, a sub-
clinical disease in the fellow eye was not excluded in these
patients by ICGA or B-scan ultrasonography before initiating
systemic corticosteroids.33e35 Again, using ICGA and/or EDI-
OCT and, when not available, B-scan ultrasonography, sub-
clinical involvement in the other eye can be detected in the
early stages of the disease and not be overlooked. Thanks to
these extremely sensitive techniques, it can be said that there isFig. 2. Follow-up of a case of initial-onset VogteKoyanagieHarada (VKH) di
after tapering of corticosteroids to 30 mg, there is subclinical recurrence with num
choroiditis after the introduction of mycophenolic acid (ICGA score ¼ 0) (2b).
chorioretinopathy, a new subclinical recurrence of choroiditis occurred with many H
choroiditis after the introduction of infliximab (2d). No recurrence after discontinno such thing as unilateral VKH. Such published cases are
simply insufficiently investigated cases where the subclinical
disease in the contralateral eye was missed.
The recently reported concept of “therapeutic window of
opportunity” indicated that the earlier therapy is given (within
the therapeutic window of opportunity), the higher the chances
of not only to achieve successful therapy but even to cure the
disease.3 Using the new sensitive diagnostic tools will con-
tribute to catch more cases within this therapeutic window of
opportunity. In the Chinese study cited above, the non-
inclusion of ICGA in their criteria is difficult to understand,
explained by its inaccessibility in China and its cost. However,
the results of this study clearly showed that ICGA was most
valuable for detecting choroidal inflammation in acute VKH
disease. Except for bilaterality, a positive ICGAwas their most
frequent finding. ICGA also had high sensitivity and specif-
icity of 80% and the best combination of positive predictive
value and negative predictive value. Therefore, the ICGA
findings should have been included in the diagnostic criteria,
an important element for rapid diagnosis especially of early-
onset disease, where rapid therapeutic intervention is critical.sease monitored by Indocyanine green angiography (ICGA). Three weeks
erous HDDs and choroidal vasculitis (ICGA score ¼ 17) (2a). Resolution of
After discontinuation of corticosteroids because of suspected central serous
DDs and choroidal vasculitis (ICGA score ¼ 20) (2c). Complete resolution of
uation of cyclosporine (2e) and discontinuation of mycophenolic acid (2f).
Fig. 3. Follow-up of a case of initial-onset VogteKoyanagieHarada (VKH)
disease monitored by enhanced depth imaging optical coherence tomog-
raphy (EDI-OCT) (average thickness indicated in yellow on scans). Three
weeks after aggressive corticosteroid and cyclosporine therapy, there was a
decrease of choroidal thickness from 550 to 375 mm with remaining pouches
of subretinal fluid (3a). After that, EDI-OCT was unable to detect subclinical
recurrences and their resolution seen by Indocyanine green angiography
(ICGA) (3b-3f), although the choroidal thickness is gradually decreasing over
time to 283 mm (3g).
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acute VKH disease. Beside fine characterization of signs, it
accelerates the diagnosis of initial-onset disease by potentially
showing subretinal fluid not detected clinically and choroidal
thickening thanks to EDI-OCT or swept-source OCT.
Considering the arguments put forward in these lines, the
approach for the diagnosis of VKH should be reconsidered and
sharpened. Based on our experience and evidence-based
medicine, we recommend to go beyond these criteria that
have neglected the crucial distinction between initial-onset and
chronic disease, and to include new and extremely sensitive
diagnostic modalities, such as ICGA, spectral or swept-source
OCT and EDI-OCT, that allow a quick diagnosis of early-onset
disease when quick, aggressive, and sustained treatment
especially matters. Adopting such an approach will lead to
successful treatment of initial-onset disease and prevention of
chronic evolution, as shown in the illustrative case below
(Figs. 1e3).
Case: the crucial role of ICGA and EDI-OCT for quick
diagnosis, prompt therapy, and precise ICGA-monitored
tapering of therapy in a case of initial-onset VKH disease
A middle-aged woman was seen for a panuveitis with
predominant posterior involvement including bilateral papil-
litis with peripapillary serous detachments. Fluorescein
angiography showed hyperfluorescent discs (Fig. 1c) and areas
of subretinal staining/pooling in the posterior pole. On ICGA,
signs characteristic of VKH were noted, such as pronounced
choroidal vasculitis (fuzzy vessels) and multiple, round,
hypofluorescent dark dots (HDDs) in the posterior pole and
evenly scattered in the periphery (Fig. 1a). Additionally, ICGA
showed hyperfluorescent discs, a finding only rarely seen and
present in pronounced choroidal inflammation (Fig. 1b). The
mean EDI-OCT thickness was difficult to measure and was
rated >550 mm, allowing a prompt diagnosis of VKH disease.
Dual inflammation suppressive treatment (IST) was given,
including IV methylprednisolone (1000 mg daily for 3 days),
followed by oral prednisone (50 mg/day) together with
cyclosporine (250 mg/day). After 3 weeks of this high dose
IST, there was a spectacular regression of ICGA signs with a
decrease in the ICGA score36 from 31 to 6, indicating that the
choroiditis seemed to be under control (Fig. 1d) with the
disappearance of ICGA disc hyperfluorescence (Fig. 1e). In
parallel, the EDI-OCT choroidal thickness decreased from 550
to 375 mm (Fig. 3a). Upon tapering of corticosteroids to
30 mg, occult subclinical recurrence occurred (Fig. 2a) that
responded to the introduction of mycophenolic acid (1400 mg/
day) (Fig. 2b). Because of suspected central serous chorior-
etinopathy, corticosteroids were discontinued, followed by a
new subclinical ICGA recurrence (Fig. 2c). EDI-OCT did not
detect these subclinical recurrences and values remained
between 387 and 369 mm (Fig. 3bed), but subsequent EDI-
OCT values decreased slightly (Fig. 3eeg). When infliximab
(5 mg/kg) was introduced, choroiditis disappeared and never
recurred, allowing discontinuation of cyclosporine and
mycophenolic acid and prolonged intervals between
6 Editorial / Journal of Current Ophthalmology 31 (2019) 1e7infliximab infusions. This case shows how combined ICGA
and EDI-OCT were very efficient in the rapid diagnosis of
VKH disease in a case with a compatible clinical picture and
how ICGA allowed the safe tapering of therapy without
recurrence.
In summary, our aims here were: (1) to stress the crucial
importance of distinguishing chronic VKH from initial-
onset disease, as the latter can be cured when diagnosed
and treated early; (2) to draw attention to the new diag-
nostic modalities available to clinicians, such as ICGA,
OCT, and EDI-OCT, that contribute to an early diagnosis,
especially of initial-onset disease and allow early and
appropriate therapy.
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